Evidence map›Paper›PMID 31332163›Full record

ArticleCell death & disease2019

CXCL12 loaded-dermal filler captures CXCR4 expressing melanoma circulating tumor cells.

Caterina Ieranò, Crescenzo D'Alterio, Simona Giarra, Maria Napolitano, Giuseppina Rea, Luigi Portella, Assunta Santagata, Anna Maria Trotta, Antonio Barbieri, Virginia Campani and 8 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Engineered immunological niche directs therapeutic development in models of progressive multiple sclerosis.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. International journal of medical sciences · 2021
    Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Caterina IeranòFunctional Genomics, Istituto Nazionale Tumori - IRCCS - Fondazione "G. Pascale", Napoli, Italy.
Crescenzo D'AlterioFunctional Genomics, Istituto Nazionale Tumori - IRCCS - Fondazione "G. Pascale", Napoli, Italy.
Simona GiarraDepartment of Pharmacy, Federico II University, Napoli, Italy.
Maria NapolitanoFunctional Genomics, Istituto Nazionale Tumori - IRCCS - Fondazione "G. Pascale", Napoli, Italy.
Giuseppina ReaFunctional Genomics, Istituto Nazionale Tumori - IRCCS - Fondazione "G. Pascale", Napoli, Italy.
Luigi PortellaFunctional Genomics, Istituto Nazionale Tumori - IRCCS - Fondazione "G. Pascale", Napoli, Italy.
Assunta SantagataFunctional Genomics, Istituto Nazionale Tumori - IRCCS - Fondazione "G. Pascale", Napoli, Italy.
Anna Maria TrottaFunctional Genomics, Istituto Nazionale Tumori - IRCCS - Fondazione "G. Pascale", Napoli, Italy.
Antonio BarbieriAnimal Facility, Istituto Nazionale Tumori - IRCCS - Fondazione "G. Pascale", Napoli, Italy.
Virginia CampaniDepartment of Pharmacy, Federico II University, Napoli, Italy.
Antonio LucianoAnimal Facility, Istituto Nazionale Tumori - IRCCS - Fondazione "G. Pascale", Napoli, Italy.
Claudio ArraAnimal Facility, Istituto Nazionale Tumori - IRCCS - Fondazione "G. Pascale", Napoli, Italy.
Anna Maria AnnicielloPathology Unit, Istituto Nazionale Tumori - IRCCS - Fondazione "G. Pascale", Napoli, Italy.
Gerardo BottiPathology Unit, Istituto Nazionale Tumori - IRCCS - Fondazione "G. Pascale", Napoli, Italy.
Laura MayolDepartment of Pharmacy, Federico II University, Napoli, Italy.
Giuseppe De RosaDepartment of Pharmacy, Federico II University, Napoli, Italy.
Roberto PacelliDepartment of Advanced Biomedical Sciences, Federico II University School of Medicine, Napoli, Italy.
Stefania ScalaFunctional Genomics, Istituto Nazionale Tumori - IRCCS - Fondazione "G. Pascale", Napoli, Italy. scalaste@gmail.com.
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITFederico II University Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Development of distant metastasis relies on interactions between cancer and stromal cells. CXCL12, also known as stromal-derived factor 1α (SDF-1α), is a major chemokine constitutively secreted in bone marrow, lymph nodes, liver and lung, playing a critical role in the migration and seeding of neoplastic cells. CXCL12 activates the CXCR4 receptor that is overexpressed in several human cancer cells. Recent evidence reveals that tumors induce pre-metastatic niches in target organ producing tumor-derived factors. Pre-metastatic niches represent a tumor growth-favoring microenvironment in absence of cancer cells. A commercially available dermal filler, hyaluronic acid (HA) -based gel, loaded with CXCL12 (CLG) reproduced a "fake" pre-metastatic niche. In vitro, B16-hCXCR4-GFP, human cxcr4 expressing murine melanoma cells efficiently migrated toward CLG. In vivo, CLGs and empty gels (EGs) were subcutaneously injected into C57BL/6 mice and 5 days later B16-hCXCR4-GFP cells were intravenously inoculated. CLGs were able to recruit a significantly higher number of B16-hCXCR4-GFP cells as compared to EGs, with reduced lung metastasis in mice carrying CLG. CLG were infiltrated by higher number of CD45-positive leukocytes, mainly neutrophils CD11b+Ly6G+ cells, myeloid CD11b+Ly6G- and macrophages F4/80. CLG recovered cells recapitulated the features of B16-hCXCR4-GFP (epithelial, melanin rich, MELAN A/ S100/ c-Kit/CXCR4 pos; α-SMA neg). Thus a HA-based dermal filler loaded with CXCL12 can attract and trap CXCR4+tumor cells. The CLG trapped cells can be recovered and biologically characterized. As a corollary, a reduction in CXCR4 dependent lung metastasis was detected.

Indexed as

AnimalsCell Line, TumorCell MovementCell SurvivalChemokine CXCL12Dermal FillersFemaleHeterograftsInjections, SubcutaneousLung NeoplasmsMelanoma, ExperimentalMiceMice, Inbred C57BLNeoplasm MetastasisNeoplastic Cells, CirculatingReceptors, CXCR4Chemokine CXCL12CXCL12 protein, humanCXCR4 protein, humanDermal FillersReceptors, CXCR4Recombinant Proteins

Identifiers

PMID31332163
PMCPMC6646345
OpenAlexW2964261409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.